



ASX ANNOUNCEMENT

14 November 2022

Renounceable Rights Offer – Despatch of Documents

Transformative, concussion management technology company, **HITIQ Limited** (ASX: **HIQ**) (**HITIQ** or the **Company**) advises that the Prospectus and Application Form for the renounceable rights issue offer (“Rights Issue Offer”) as announced to the ASX on 1 November 2022 has been despatched.

As announced, the Company is undertaking the Rights Issue Offer to eligible shareholders to subscribe for eight (8) New Shares for every five (5) Shares held at an offer price of \$0.03 (3 cents) per share plus one (1) free attaching Option for every one (1) New Share subscribed under the Offer to raise up to \$6.35 million before costs. Eligible shareholders are shareholders with a registered address in Australia or New Zealand as at as at the Record Date of 10th November 2022. The Rights Issue Offer has a minimum subscription of \$2 million.

Rights Issue participants will be offered attaching unlisted Options for every one new share taken up. The Company confirms that the Options will have an exercise price of \$0.04 and will expire on 9th December 2023.

Notifications have been sent to existing Option holders and ineligible foreign shareholders pursuant to ASX Listing Rules.

- ENDS -

Authorised for release by the Managing Director.

For more information, contact:

Mike Vegar
CEO & MD
HITIQ Limited
investors@hitiq.com

Elvis Jurcevic
Investor Relations
+61 408 268 271
ej@hitiq.com

HITIQ Limited
ACN 609 543 213
ASX: **HIQ**

HITIQ.COM

Corporate Office
Level 2, 9-17 Raglan Street
South Melbourne VIC 3205

E: investors@hitiq.com

Directors

Otto Buttula
Michael Vegar
Phillip Carulli
Glenn Smith
Aidan Clarke

Non-Executive Chair
Managing Director
Non-Executive Director
Non-Executive Director
Non-Executive Director

About HITIQ

HITIQ Limited (ASX: **HIQ**) operates in the healthcare equipment sector, providing and further developing a transformative, end-to-end concussion management technology platform. This platform aims to provide a total concussion ecosystem whereby the Company's products support the identification, monitoring and management of sport related brain injury. HITIQ's product suite utilises high-end technology that will span multiple domains – from early detection and surveillance to assessment and rehabilitation technology tools.

HITIQ is targeting a growing worldwide concussion management market including elite and recreational sport, clinical practitioners, military, research, and combat sports. The Company's first commercial partner is the Australian Football League, with current strategy initiatives expanding commercially into Rugby League, Rugby Union, Ice Hockey, Lacrosse, MMA and American Football (particularly the NCAA). The market opportunity globally represents ~500k athletes within the elite market and ~10million in the consumer market.